hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06303115 id: CSD231005 BoE briefTitle: CSD231005 Nicotine Pouch Biomarkers of Exposure overallStatus: NOT_YET_RECRUITING date: 2024-07-15 date: 2024-12-15 date: 2025-01-15 date: 2024-03-12 date: 2024-03-15 name: RAI Services Company class: INDUSTRY briefSummary: This will be a multi center open label, randomized, controlled, switching parallel-group study designed to assess changes in select biomarkers of exposure (BoE) in generally healthy smokers following a 5 day in-clinic switch to use of nicotine Pouch investigational products (IPs) compared to continued usual brand (UB) cigarette smoking or smoking abstinence. conditions: Tobacco Use conditions: Smoking studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 200 type: ESTIMATED name: Nicotine Pouch P1312914, 4 mg nicotine name: Nicotine Pouch P1312915, 8 mg nicotine name: Nicotine Pouch P1013215, 8 mg nicotine name: Nicotine Pouch P1013218, 10 mg nicotine name: Nicotine Pouch P1012919, 12 mg nicotine name: Smoking Abstinence name: Continued UB cigarette smoking measure: 4(methylnitrosamino)1(3pyridyl)1butanol [NNAL] + glucuronides [Total NNAL] measure: 4Aminobiphenyl [4ABP] measure: 1Aminonaphthalene [1AN] measure: 2Aminonaphthalene [2AN] measure: 2Cyanoethyl mercapturic acid [CEMA] measure: 3Hydroxypropyl mercapturic acid [3HPMA] measure: 3Hydroxy1methylpropylmercapturic acid [HMPMA] measure: 3hydroxybenzo[a]pyrene [3-OH-B[a]P] measure: 1hydroxypyrene [1OHP] measure: Monohydroxybutyl mercapturic acid [MHBMA] measure: Nnitrosonornicotine [NNN] + glucuronides [Total NNN] measure: SPhenyl mercapturic acid [SPMA] measure: Total nicotine equivalents (molar sum of nicotine, cotinine, 3hydroxycotinine and their glucuronides) [TNneq] measure: Carboxyhemoglobin [COHb] measure: Nnitrosonornicotine [NNN] + glucuronides [Total NNN] sex: ALL minimumAge: 21 Years maximumAge: 60 Years stdAges: ADULT facility: Pillar Bentonville city: Bentonville state: Arkansas zip: 72712 country: United States lat: 36.37285 lon: -94.20882 facility: AMR Lexington city: Lexington state: Kentucky zip: 40509 country: United States lat: 37.98869 lon: -84.47772 facility: QPS Missouri city: Springfield state: Missouri zip: 65802 country: United States lat: 37.21533 lon: -93.29824 facility: AMR Knoxville city: Knoxville state: Tennessee zip: 37920 country: United States name: William Smith, MD role: CONTACT lat: 35.96064 lon: -83.92074 facility: Pillar Richardson city: Richardson state: Texas zip: 75080 country: United States lat: 32.94818 lon: -96.72972 hasResults: False
nctId: NCT06303102 id: REC/RCR&AHS/23/0356 briefTitle: Effects of Segmental and Pursed Lip Breathing Exercises on Upper Cross Syndrome overallStatus: COMPLETED date: 2023-05-23 date: 2024-01-30 date: 2024-02-15 date: 2024-03-12 date: 2024-03-12 name: Riphah International University class: OTHER briefSummary: Upper cross syndrome is relative prevalent 67% musculoskeletal disorder among general population due to increased usage of smart gadgets and poor postural habits. Upper cross syndrome is known for initiating malfunction of cervical and upper back muscles also associated with respiration. Individuals with upper cross syndrome may present with relaxed supine positioning, they may having normal respiratory mechanics but might be converted to accessory muscles activated pattern. Neck pain is the most common type of pain in non-traumatic conditions, affecting about 75.7% of people. The aim of this study is to compare the effects of segmental and pursed lip breathing exercises on pain, functional disability and quality of life in population with upper cross syndrome.
Current study will be randomized controlled trial conducted at Ismail Medicare Jhang, 40 patients according to inclusion criteria will be included in the study. They will be allocated into 2 groups by non-probability purposive sampling technique. Group A (control group) will receive conventional physical therapy treatment (hot pack, electrical stimulation, myofascial release, ROM and strengthening exercises) while Group B (experimental group) receive conventional physical therapy treatment with segmental and pursed lip breathing exercises. Outcome measures are Pain Numeric Scale, Quality of life (SF 36) and Functional disability (neck disability index). These tools will measure neck function and neck pain intensity. Treatment time will be 4 weeks, 3 sessions per week, each session will be 45 minutes long, and measurements will be taken after 4 weeks. Data will be analyzed by SPSS version 25. After assessing normality of data by Shapiro - wilk test, it will be decided either parametric or non-parametric test will be used within a group or between two groups analysis.
Key Words: Breathing Exercises, Cervical Pain, Disability, Upper Cross conditions: UPPER CROSS SYNDROME studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 40 type: ACTUAL name: Manual PT/ Conventional PT Treatment + Segmental and Pursed Lip Breathing Exercise name: Manual PT/Conventional PT Treatment measure: NPRS measure: Quality of Life (SF-36 questionnaire) measure: Neck Disability Index (NDI) sex: ALL minimumAge: 25 Years maximumAge: 40 Years stdAges: ADULT facility: Ismail Medicare city: Jhang state: Punjab zip: 35200 country: Pakistan hasResults: False
nctId: NCT06303089 id: zzwee-quit (CKD) 23152 briefTitle: Tobacco Exposure and Influencing Factors of Smoking Cessation Among Chronic Kidney Disease Patients overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-01-01 date: 2025-03-01 date: 2024-03-12 date: 2024-03-12 name: Sun Yat-sen University class: OTHER briefSummary: The purpose of this study is to describe the tobacco exposure and characteristics of patients with Chronic Kidney Disease (CKD) who quit smoking, to identify patients' tobacco-related knowledge, attitude, and practice (KAP) and explore the influencing factors of smoking cessation. conditions: Smoking Cessation studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 554 type: ESTIMATED name: Questionnaires set measure: Prevalence of current smokers measure: Abstinence rates measure: Nicotine dependence measure: Perceptions of tobacco harm measure: knowledge of tobacco-related diseases measure: Smoking related attitudes measure: Self-efficacy level measure: Withdrawal symptoms sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: XIAW city: Guangzhou state: Guangdong zip: 510080 country: China name: Wei Xia, PhD role: CONTACT phone: 18823359471 email: xiaw23@mail.sysu.edu.cn lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06303076 id: 134 briefTitle: Tizanidine vs. Zolpidem in Primary Insomnia: A Randomized Trial overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2026-09 date: 2026-12 date: 2024-03-12 date: 2024-03-12 name: Sultan Qaboos University class: OTHER briefSummary: The study's primary objective is to evaluate the effectiveness of Tinazidine compared to Zolpidem in enhancing sleep quality, with secondary objectives including the assessment of adverse effects, safety profile, and patient tolerance with each treatment. The trial will be conducted as a double-blind RCT, with participants randomly assigned to receive either Tinazidine (0.1 mg/Kg/HS) or Zolpidem 10 mg HS, for 12 weeks. Eligible participants, aged 18-60 years, diagnosed with primary insomnia as per DSM-5 criteria, will be recruited from an outpatient sleep clinic affiliated with Al-Masara Hospital. Data on sleep quality, and side effects, will be collected using the Sleep Pittsburgh Sleep Quality Index (PSQI), Clinical Global Impression (CGI), sleep diaries, actigraphy, polysomnography, and regular clinical interview though OPD follow-up visits. The primary outcome considered was the mean global PSQI score before and after the treatment. The primary outcome will be measured four times (baseline, 4 weeks, 8 weeks, and 12 weeks), We considered an attrition rate (dropout/lost follow-up) of 10%. Therefore, the sample size is 90 subjects (45 in each group). Group comparisons for mean scores will be conducted using independent samples t-tests, and within-group comparisons will be assessed using paired samples t-tests. Changes in sleep quality over time between treatment groups will be evaluated using repeated measures ANOVA. Associations between categorical variables will be examined using Chi-square tests (including Fisher's exact or Likelihood ratio tests as appropriate). Statistical significance will be considered for p-values less than 0.05. All analyses will be performed using IBM SPSS Statistics (Version 29.0). The findings of this study seek to elucidate the comparative efficacy and safety profiles of Tizanidine and Zolpidem in treating primary insomnia. The study aims to offer insights into the effectiveness of Tizanidine versus Zolpidem in improving sleep quality among patients with primary insomnia. Through the evaluation of efficacy, adverse effects, and safety profiles. This study aims to inform clinicians and healthcare practitioners about the optimal treatment choices for individuals with primary insomnia. conditions: Depressive Disorder, Major studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 90 type: ESTIMATED name: Tizanidine Hcl 4Mg Tab name: Zolpidem Tartrate 10 mg measure: Pittsburgh Sleep Quality Index measure: Frequency and Severity of Side Effects sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06303063 id: SNSC-IAS-202301 briefTitle: Compare the Safety and Effectiveness of Two Different Kinds of Stent System in Intracranial Aneurysms overallStatus: RECRUITING date: 2024-01-17 date: 2025-06-30 date: 2025-12-30 date: 2024-03-12 date: 2024-04-01 name: Sinomed Neurovita Technology Inc. class: INDUSTRY briefSummary: The primary objective of this trial is to evaluate the safety and efficacy of SINOMED IAS in patients with intracranial aneurysms. conditions: Intracranial Aneurysm studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 204 type: ESTIMATED name: SINOMED IAS Stent System name: Neuroform Atlas Stent System measure: Success aneurysm occlusion at 6 month post procedure measure: Technical success measure: Success aneurysm occlusion immediately after the procedure measure: Complete aneurysm occlusion without significant parent artery stenosis (≤50%) or retreatment at 6 months post procedure measure: Complete aneurysm occlusion at 6 months post procedure measure: Retreatment Rate at 6 months and 1 year post procedure measure: In-Stent Stenosis at 6 months post procedure measure: Modified Rankin Scale (mRS) at 30 days, 6 months and 1 year post procedure measure: Major ipsilateral stroke at 30 days, 6 months and 1 year post procedure measure: All-cause mortality at 30 days, 6 months and 1 year post procedure measure: Incidence of adverse events/serious adverse events during 30 days, 6 months and 1 year post procedure measure: In-stent thrombosis at 6 months post procedure measure: Rate of Device defect sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Tiantan Hospital, Capital Medical University status: RECRUITING city: Beijing country: China name: Jianxin Yang role: CONTACT phone: 010-59978595 email: yangxinjian@voiceoftiantan.org lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06303050 id: Urooj Amir briefTitle: Additional Effects of Mental Imagery Along With Task Oriented Training on Kinesiophobia in Patients With Stroke overallStatus: RECRUITING date: 2023-12-07 date: 2024-06-07 date: 2024-06-07 date: 2024-03-12 date: 2024-03-12 name: Riphah International University class: OTHER briefSummary: The objective of this study to determine the effect of mental imagery and task oriented training on Kinesiophobia in stroke patients. And to determine the association of Kinesiophobia with gait and balance in stroke patients. Patients will be divided into experimental and control group. Randomized participants will be allocated into control and experimental group. The experimental group will receive 20 minutes of MI training followed by 25 minutes of TOT for a total of 45 minutes, 5 days per week for 6 weeks. conditions: Stroke, Cardiovascular studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 44 type: ESTIMATED name: Mental Imagery with task Oriented training group name: Task Oriented training group measure: Berg And Balance scale measure: Tempa scale for kinesiophobia measure: Ten-meter walk test measure: Dynamic gate index measure: Time Up and Go Test sex: ALL minimumAge: 45 Years maximumAge: 60 Years stdAges: ADULT facility: Khyber Medical University status: RECRUITING city: Peshawar state: KPK zip: 2500 country: Pakistan name: Nadia Azhar, NMPT role: CONTACT phone: 03335281431 email: nadia.azhar@riphah.edu.pk lat: 34.008 lon: 71.57849 hasResults: False
nctId: NCT06303037 id: SAHoWMU-CR2024-03-105 briefTitle: Effect of Esketamine on 95% Induction Dose of Remimazolam acronym: EEIDR overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-02 date: 2025-03 date: 2024-03-12 date: 2024-03-12 name: Second Affiliated Hospital of Wenzhou Medical University class: OTHER briefSummary: As an invasive operation, gastroscopy will cause children's nervousness, anxiety and uncooperative behavior, and even lead to the risk of bleeding and perforation, which will also affect the accuracy of the examination results.The purpose of this study is to explore the influence of different doses of esketamine on the induced dose ED95 of remazolam during gastroscopic placement in children, and to provide theoretical basis for the combined use of remimazolam besylate and esketamine in gastroscopic anesthesia in children. conditions: Pediatric conditions: Gastroscopy conditions: ED95 conditions: Sedation studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Remimazolam besylate and low-dose Esketamine name: Remimazolam besylate and Medium dose Esketamine measure: Sedation induction time measure: Modified observer's assessment of alertness#sedation#MOAA/S#scale measure: Recovery times measure: VAS(The difficulty of gastroscope insertion) measure: Number of children with adverse effects sex: ALL minimumAge: 3 Years maximumAge: 12 Years stdAges: CHILD facility: The second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University city: Wenzhou state: Zhejiang country: China lat: 27.99942 lon: 120.66682 hasResults: False
nctId: NCT06303024 id: RELIABLE Clinical Study briefTitle: Targeting Subclinical Motor and Cognitive Impairment in Patients With Early Onset Multiple Sclerosis acronym: RELIABLE overallStatus: RECRUITING date: 2023-06-14 date: 2024-03-01 date: 2026-03-01 date: 2024-03-12 date: 2024-03-12 name: Fondazione Don Carlo Gnocchi Onlus class: OTHER name: Careggi Hospital name: Sheba Medical Center name: Uppsala University briefSummary: Our project proposal is based on an individualized rehabilitation approach in patients with early stage relapsing remission (RR) MS. This approach will be based on risk stratification obtained using several clinical and demographic parameters that are not commonly used in clinical practice. This risk score will be obtained from an extensive neuropsychological, psychosocial and physical assessment to which patients will undergo at baseline and at one-year follow-up.The risk score will allow a better stratification of patients' risk of disease worsening/progression and the application of a preventive and personalized strategy. conditions: Multiple Sclerosis, Relapsing-Remitting studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SEQUENTIAL interventionModelDescription: This is a multicentric no-profit pilot study, composed by two phases. I phase: observational prospective study II phase: interventional study primaryPurpose: TREATMENT masking: NONE count: 140 type: ESTIMATED name: personalized combined physical and cognitive intervention measure: Symbol Digit Modalities Test (SDMT) measure: California Verbal Learning Test second edition (CVLT-II) measure: Brief Visuo-Spatial Memory Test- Revised (BVMT-R) measure: Word list generation (WLG) measure: Stroop test measure: Test Intelligenza Breve (TIB) measure: 9 hole peg test (9HPT) measure: The Hospital Anxiety and Depression Scale (HADS) measure: Beck Depression Inventory second edition measure: The Modified Fatigue Impact Scale (MFIS) measure: The Multiple Sclerosis Walking Scale (MSWS-12) measure: Multiple Sclerosis Impact Scale (MSIS-29-V2) measure: Multiple Sclerosis Quality of Life-54 (MSQOL-54) measure: six minutes walking test (6MWT) measure: Romberg test measure: handgrip test measure: cognitive-motor interference measure: Timed 25-foot walk measure: brain MRI scan measure: International Physical Activity Questionnaire (IPAQ) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Fondazione Don Carlo Gnocchi ONLUS status: RECRUITING city: Firenze zip: 50143 country: Italy name: Maria Pia Amato, Prof role: CONTACT phone: 0557947836 email: mpamato@dongnocchi.it lat: 43.77925 lon: 11.24626 hasResults: False
nctId: NCT06303011 id: S22C14G92003 briefTitle: Abdominal Massage With TENS on Parasacral Versus Sacral Area on Symptom,Severity & QOL in Chronic Constipation Females. overallStatus: COMPLETED date: 2023-03-15 date: 2024-03-15 date: 2024-03-15 date: 2024-03-12 date: 2024-04-22 name: Riphah International University class: OTHER briefSummary: Constipation is Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections. Patients complaining of constipation may mean different things by the term The frequency of their bowel actions may be less than 'normal', their stools maybe difficult to pass, or they may have a sense of malaise or abdominal discomfort which they attribute to a 'sluggish bowel', though the stool frequency and consistency are apparently normal. Objective of this study is to compare effects of Abdominal massage. withTENSonparasacralversussacralareaonsymptomseverityandqualityoflifein severechronicconstipationamongyoungfemales. conditions: Constipation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 26 type: ACTUAL name: Transcutaneous Electrical Nerve Stimulator name: TENS on para sacral area with Abdominal Massage measure: PAC-SYM Questionnaire measure: PAC-QOL Questionnaire sex: FEMALE minimumAge: 14 Years maximumAge: 35 Years stdAges: CHILD stdAges: ADULT facility: Jinnah Hospital city: Lahore state: Punjab zip: 44000 country: Pakistan lat: 31.558 lon: 74.35071 hasResults: False
nctId: NCT06302998 id: MS.111 briefTitle: Dexmedetomidine and Vasopressin in Septic Shock acronym: DecatSepsis-2 overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-12 date: 2026-01 date: 2024-03-12 date: 2024-03-12 name: Mansoura University class: OTHER briefSummary: Rudiger and Singer suggested strategies for refining adrenergic stress (decatecholaminization). They proposed the use of dexmedetomidine and vasopressin to reduce the catecholamine load during sepsis. The investigators will use vasopressin as the primary vasopressor and a heart rate-calibrated dexmedetomidine infusion in septic shock patients.
The investigators of the current study will use DEXPRESSIN in septic shock patients to investigate the effects of decatecholaminization on in-hospital mortality. conditions: Sepsis conditions: Septic Shock studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized controlled superiority trial primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The outcome assessor will be nurses - not invovled in the study - will be unware about the study drug. whoMasked: OUTCOMES_ASSESSOR count: 260 type: ESTIMATED name: DEX-PRESSIN name: Standard of Care measure: in-hospital mortality measure: survival analysis measure: Norepinephrine Equivalent Dose (NED) measure: Duration of vasopressor infusion in survivors measure: Initiation of invasive mechanical ventilation (IMV) measure: Duration of IMV measure: Early acute kidney injury (AKI) measure: Late acute kidney injury (AKI) measure: Acute Physiology and Chronic Health Evaluation (APACHE-II) measure: Simplified Acute Physiology Score (SAPS) II score measure: ICU length of stay measure: Hospital length of stay sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06302985 id: ICG-CLMs briefTitle: Atomized Inhalation ICG for Treatment of Congenital Lung Malformations overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2050-12-31 date: 2050-12-31 date: 2024-03-12 date: 2024-03-12 name: Jiexiong Feng class: OTHER briefSummary: To investigate the safety and effectiveness of preoperative aerosol inhalation ICG solution for thoracoscopic accurate resection of congenital lung malformations in children. conditions: Pulmonary Sequestration conditions: Congenital Pulmonary Airway Malformation conditions: Indocyanine Green conditions: Thoracoscopic Surgery conditions: Children studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: atomized inhalation ICG before thoracoscope pneumonectomy measure: rate residual measure: peak volume ratio measure: length of hospital stay measure: peak time ratio sex: ALL minimumAge: 3 Months maximumAge: 14 Years stdAges: CHILD facility: Tongji Hospital city: Wuhan state: Hubei zip: 430030 country: China lat: 30.58333 lon: 114.26667 hasResults: False